5MPN is a selective, orally active inhibitor of PFKFB4 that competitively targets its F6P binding site. This compound suppresses myeloma cell proliferation in vitro and is a useful tool for investigating metabolic dysregulation in hematological cancers like myeloproliferative neoplasms.